Last reviewed · How we verify
Imiquimod cream + surgery
Imiquimod cream activates toll-like receptors to stimulate local immune response, combined with surgical removal to treat skin lesions.
Imiquimod cream activates toll-like receptors to stimulate local immune response, combined with surgical removal to treat skin lesions. Used for Basal cell carcinoma (adjuvant to surgery), Cutaneous melanoma (adjuvant to surgery).
At a glance
| Generic name | Imiquimod cream + surgery |
|---|---|
| Sponsor | Nantes University Hospital |
| Drug class | Toll-like receptor agonist (topical immune response modifier) |
| Target | TLR7, TLR8 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Imiquimod is a topical immune response modifier that binds to TLR7 and TLR8, triggering innate immune activation and promoting Th1 cytokine production at the application site. When combined with surgical excision, this approach aims to reduce recurrence by eliminating the lesion while enhancing local anti-tumor immunity. This combination strategy is being evaluated in phase 3 trials for skin cancer indications.
Approved indications
- Basal cell carcinoma (adjuvant to surgery)
- Cutaneous melanoma (adjuvant to surgery)
Common side effects
- Local skin irritation (erythema, erosion)
- Pruritus
- Systemic flu-like symptoms
- Lymphadenopathy
Key clinical trials
- Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC (PHASE1)
- Radiotherapy or Imiquimod in Complex Lentigo Maligna (PHASE3)
- Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face (PHASE3)
- Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma (PHASE1)
- Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma (PHASE3)
- Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia (PHASE3)
- Imiquimod for Preventing Keloid Recurrence (PHASE2)
- Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imiquimod cream + surgery CI brief — competitive landscape report
- Imiquimod cream + surgery updates RSS · CI watch RSS
- Nantes University Hospital portfolio CI